Mechanisms of FK 506-Induced Hypertension in the Rat

Hypertension

Volumn 33, Issue 1, 1999, Pages 130-136

  Takeda, Yoshiyu ^a   Miyamori, Isamu ^a   Furukawa, Kenji ^a   Inaba, Satoru ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE REGULATION; DRUG EFFECT; HYPERTENSION; MALE; MESENTERIC ARTERY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RAT;

ANIMALS; AORTA, ABDOMINAL; ASPARTIC ENDOPEPTIDASES; AZEPINES; BASE SEQUENCE; BLOOD PRESSURE; BLOTTING, SOUTHERN; DATA INTERPRETATION, STATISTICAL; DNA, COMPLEMENTARY; ENDOTHELIN-1; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INDOLES; KIDNEY; MALE; MESENTERIC ARTERY, SUPERIOR; METALLOENDOPEPTIDASES; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, C-TYPE; NITRIC OXIDE SYNTHASE; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED WKY; RNA, MESSENGER; TACROLIMUS;

EID: 0032918984     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.33.1.130     Document Type: Article

References (50)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, H. Imanaka H. FK-506, a novel immunosuppressant isolated from a Streptomyces, I: fermentation, isolation, and physicochemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249-1255.
2. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhama M, Kohsaka M, Aoki H, Ochiai T. FK-506, a novel immunosuppressant isolated from a Streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40:1256-1265.
3. Goto T, Kino T, Hatanaka M, Kohsaka M, Aoki H, Imanaka H. FK 506: historical perspectives. Transplant Proc. 1991;23:2713-2717.
4. Benett WM. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol. 1995;43(suppl 1):S3-S7.
5. Textor SC. De-novo hypertension after liver transplantation. Hypertension. 1993;22:257-267.
6. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110-1115.
7. Sturrock NDC, Lang CC, Struthers AD. Cyclosporine-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens. 1993;11:1209-1216.
8. Golbaekdal K, Nielsen CB, Pedersen EB. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. J Pharm Pharmacol. 1996;48:1174-1179.
9. Textor SC, Russell R, Wilson DJ, Porayko M, Carlos Romero J, Burnett JC Jr, Gores G, Hay E, Dickson ER, Krom RA. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993;55:1332-1339.
10. Takeda Y, Yoneda T, Ito Y, Miyamori I, R. Takeda R. Stimulation of endothelin mRNA and secretion in human endothelial cells by FK 506. J Cardiovasc Pharmacol. 1993;22(suppl 8):S310-S312.
11. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet. 1992;340:622. Letter.
12. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375-3378.
13. Sogabe K, Nirei H, Shoubo M, Nomoto A, Ao S, Notsu Y, On T. Pharmacological profile of FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1993;264:1040-1046.
14. Miyamori I, Brown MJ, Dollery CT. Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin. Clin Exp Hypertens. 1980;2:935-945.
15. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension. 1995;26:932-936.
16. McGregor DD. The effect of sympathetic nerve stimulation on vasoconstrictor responses in perfused mesenteric blood vessels of the rat. J Physiol. 1965;117:21-30.
17. Takeda Y, Miyamori I, Yoneda T, Takeda R. Increased concentration of endothelin messenger RNA in the mesenteric arteries of cyclosporine-induced hypertensive rats. Am J Hypertens. 1993;6:427-430.
18. Takeda Y, Miyamori I. Yoneda T, Takeda R. Endothelin-1 release from the mesenteric arteries of cyclosporine-treated rats. Eur J Pharmacol. 1992;213:445-447.
19. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle protein-dye binding. Anal Biochem. 1976;72:248-252.
20. Rees D, Ben-Ishay D, Moncada S. Nitric oxide and the regulation of blood pressure in the hypertension-prone and hypertension-resistant Sabra rat. Hypertension. 1996;28:367-371.
21. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, Mabuchi H, Takeda R. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab. 1996;81:2797-2800.
22. Iwasaki S. Homma T, Kon V. Site specific regulation in the kidney of endothelin and its receptor subtypes by cyclosporine. Kidney Int. 1994;45:592-597.
23. Brown J, Chen Q, Hong G. An autocrine system for C-type natriuretic peptide within rat carotid neointima during arterial repair. Am J Physiol. 1997;272:H2919-H2931.
24. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem. 1994;269:18275-18278.
25. Van Voorhis BJ, Moore K, Strijbos PJL, Nelson S, Baylis SA, Grzybicki D, Weiner CP. Expression and localization of inducible and endothelial nitric oxide synthase in the rat ovary. J Clin Invest. 1995;96:2719-2726.
26. Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. J Clin Invest. 1993;91:2058-2064.
27. Takahara S, Jiang H, Ishibashi M, Okuyama A, Sonoda T. Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK 506. J Clin Lab Immunol. 1991;34:179-181.
28. Ochiai T, Isono K. Pharmacokinetics and clinical effects of FK 506. Biotherapy. 1991;5:1531-1536.
29. Ohara K, Billington R, James RW, Dean GA, Nishiyama M, Noguchi H. Toxicologic evaluation of FK 506. Transplant Proc. 1990;22(suppl 1):83-86.
30. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WSS, Epstein S. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK 506 on bone mineral metabolism in vivo. Transplantation. 1994;57:1231-1237.
31. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanisms of endothelin regulation. Circulation. 1991;84:1457-1468.
32. Miyamori I, Takeda Y, Yoneda T, Takeda R. Endothelin release from the mesenteric arteries in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1991;17:S408-S410.
33. Niranjan V, Telemaque S, deWit D, Gerard RD, Yanagisawa M. Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest. 1996;98:2364-2372.
34. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Takano Y, Kodado Y, Takahara S, Jiang H, Sonoda T, Okuyama A. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. Transplant Proc. 1991;23:3133-3136.
35. Disashi T, Nonoguchi H, Iwaoka T, Naomi S, Nakayama Y, Shimada K, Tanawa K. Endothelin converting enzyme-1 gene expression in the kidney of spontaneously hypertensive rats. Hypertension. 1997;30:1591-1597.
36. Abassi ZA, Pieruzzi F, Nakhoul F, Keiser HR. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension. 1996;27:1140-1148.
37. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
38. Panza JA, Quyyumi, AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
39. Koller A, Huang A. Impaired nitric oxide-mediated flow-induced dilation in arterioles of spontaneously hypertensive rats. Circ Res. 1994;74:416-421.
40. Stroes ESG. Luscher TF, de Groot FG, Koomans HA, Rabelink TJ. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 1997;29:570-575.
41. Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension. 1995;25:764-768.
42. Conde M, Andrade J, Bedoya FJ, Santa Maria C, Sobrino F. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology. 1995;84:476-481.
43. Kullo IJ, Mozes G, Schwartz RS, Gloviczki P, Tsutui M, Katusic ZS, O'Brien T. Enhanced endothelium-dependent relaxations after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries. Hypertension. 1997;30:314-320.
44. Scherrer U, Vidding SF, Morgan BJ, Rollins JA, Tindall RSA, Ring S, Hanson P, Mohanty PK, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693-699.
45. Canzanello VJ, Textor SC, Taler SJ, Wilson DJ, Schwartz L, Wiesner RH, Porayko MK, Krom RA. Renal sodium handling with cyclosporin A and FK 506 after orthotopic liver transplantation. J Am Soc Nephrol. 1995;5:1910-1917.
46. Shaw KTY, Ho AM, Raghavan A, Kim J, Jian J, Park J, Sharma S, Rao A, Hogan PG. Immunosuppressive drugs prevent a rapid dephosphorylation of transcription factor NFAT1 in stimulated immune cells. Proc Natl Acad Sci U S A. 1995;92:11205-11209.
47. Kirk AD, Jacobson LM, Heisey DM, Fass NA, Sollinger HW, Pirsch JD. Posttransplant diastolic hypertension: associations with intragraft transforming growth factor-beta, endothelin, and renin transcription. Transplantation. 1997;64:1716-1720.
48. Akita K, Dusting GJ, Hickey H. Suppression of nitric oxide production by cyclosporin A and FK 506 in rat vascular smooth muscle cells. Clin Exp Pharmacol Physiol. 1994;21:231-233.
49. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.
50. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.